A methylation and protein classifier was tested on 6,352 samples, 1,438 of them cancers, across 21 tumour organ types and all stages. Overall sensitivity was 50.9% at a specificity of 98.5%, measured against known cancers rather than a screening population. Sensitivity was 15.4% at stage I, rising to 85.5% at stage IV.
Why it is interesting: The test detected most late-stage cancers but fewer than one in six at stage I.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.